In the INMARK trial in subjects with IPF and preserved FVC, circulating levels of CRPM, C3M, CRP, KL-6 and SP-D at baseline were not significantly associated with disease progression over 52 weeks in analyses corrected for multiple comparisons. The gene discussed is SH3BP2; the disease is idiopathic pulmonary fibrosis.